Journal of Hypertension · 2008 · 232 citations · 23 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyPharmacovigilancePreventive CardiologyAtrial FibrillationCardiac MedicationsCardiac PharmacotherapyCardiac Risk AssessmentCardiovascular PharmacologyHypertension PharmacotherapyAngiotensin Ii Receptor BlockersAngiotensin Ii TherapyAntihypertensive PharmacologyAntihypertensive TreatmentAtrial Fibrillation In HypertensionAtrial Fibrillation Risk AssessmentCardiovascular Risk MarkersRenin-angiotensin System Blockade
BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia and increases cardiovascular risk in hypertensive patients. Therefore, in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) a prespecified objective was to compare the effects of valsartan and amlodipine on new-onset AF. METHODS: A total of 15 245 hypertensive patients at high cardiovascular risk received valsartan 80-160 mg/day or amlodipine 5-10 mg/day combined with additional antihypertensive agents. Electrocardiograms were obtained every year and analyzed centrally for evidence of left ventricular hypertrophy and new-onset AF. RESULTS: At baseline, AF was diagnosed in 2.6% of 7649 valsartan recipients and 2.6% of 7596 amlodipine recipients. During antihypertensive treatment the incidence of at least one documented occurrence of new-onset AF was 3.67% with valsartan and 4.34% with amlodipine [unadjusted hazard ratio 0.843, [95% confidence interval (CI): 0.713, 0.997], P = 0.0455]. The incidence of persistent AF was 1.35% with valsartan and 1.97% with amlodipine [unadjusted hazard ratio 0.683 (95% CI: 0.525, 0.889), P = 0.0046]. CONCLUSIONS: Valsartan-based treatment reduced the development of new-onset AF, particularly sustained AF in hypertensive patients, compared with amlodipine-based therapy. These findings suggest that angiotensin II receptor blockers may result in greater benefits than calcium antagonists in hypertensive patients at risk of new-onset AF.
23
Impact of Atrial Fibrillation on the Risk of Death
Emelia J. Benjamin, Philip A. Wolf, Ralph B. D’Agostino et al. · Circulation · 1998 · 4.6K citations
Medicine, Cardiology, Aging +16
William B. Kannel, Philip A. Wolf, Emelia J. Benjamin et al. · The American Journal of Cardiology · 1998 · 2K citations
Lennart Hansson, Lars Lindholm, Leo Niskanen et al. · The Lancet · 1999 · 2K citations
Medicine, Cardiology, Pharmacology +16
Lennart Hansson, Lars Lindholm, Tord Ekbom et al. · The Lancet · 1999 · 1.4K citations